Biomerica (BMRA) Competitors $3.47 +0.06 (+1.76%) Closing price 04:00 PM EasternExtended Trading$3.42 -0.05 (-1.30%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. MURA, MAAQ, JATT, BTAI, SNYR, DYAI, KZR, CVKD, TENX, and MIRAShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), JATT Acquisition (JATT), BioXcel Therapeutics (BTAI), Synergy CHC (SNYR), Dyadic International (DYAI), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Mural Oncology Mana Capital Acquisition JATT Acquisition BioXcel Therapeutics Synergy CHC Dyadic International Kezar Life Sciences Cadrenal Therapeutics Tenax Therapeutics MIRA Pharmaceuticals Mural Oncology (NASDAQ:MURA) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk. Do insiders and institutionals believe in MURA or BMRA? 80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 2.2% of Mural Oncology shares are owned by company insiders. Comparatively, 15.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer MURA or BMRA? In the previous week, Mural Oncology had 6 more articles in the media than Biomerica. MarketBeat recorded 6 mentions for Mural Oncology and 0 mentions for Biomerica. Mural Oncology's average media sentiment score of 0.16 beat Biomerica's score of 0.00 indicating that Mural Oncology is being referred to more favorably in the media. Company Overall Sentiment Mural Oncology Neutral Biomerica Neutral Which has more risk & volatility, MURA or BMRA? Mural Oncology has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Do analysts recommend MURA or BMRA? Mural Oncology currently has a consensus price target of $12.00, indicating a potential upside of 476.92%. Given Mural Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Mural Oncology is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, MURA or BMRA? Biomerica has higher revenue and earnings than Mural Oncology. Biomerica is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$128.51M-$8.59-0.24Biomerica$5.68M1.56-$5.98M-$2.32-1.50 Is MURA or BMRA more profitable? Mural Oncology has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -107.76% -87.57% Biomerica -85.42%-85.90%-61.06% SummaryMural Oncology beats Biomerica on 9 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.84M$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-1.5022.6131.1525.96Price / Sales1.56751.86475.15122.97Price / CashN/A173.2237.1558.38Price / Book1.115.869.116.39Net Income-$5.98M$31.83M$3.26B$265.56M7 Day Performance9.46%1.80%2.11%1.98%1 Month Performance-3.61%4.36%5.12%1.33%1 Year Performance-0.08%11.44%31.25%21.15% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.8412 of 5 stars$3.47+1.8%N/A-2.1%$8.84M$5.68M-1.5060Upcoming EarningsShort Interest ↓MURAMural Oncology3.0408 of 5 stars$1.78-2.0%$12.00+572.6%-37.1%$30.75MN/A-0.21119MAAQMana Capital AcquisitionN/A$3.72+2.5%N/A+678.0%$30.23MN/A0.001JATTJATT AcquisitionN/A$1.74+4.8%N/A-50.7%$30.02MN/A0.003Gap UpHigh Trading VolumeBTAIBioXcel Therapeutics4.5931 of 5 stars$4.93-13.0%$39.75+706.0%-52.0%$29.83M$2.27M-0.3990Short Interest ↓SNYRSynergy CHC4.4014 of 5 stars$3.20-8.0%$10.00+212.5%N/A$29.42M$33.70M8.4240DYAIDyadic International3.3166 of 5 stars$0.80+0.7%$6.00+649.1%-40.8%$28.99M$3.49M-4.227Gap UpKZRKezar Life Sciences3.8571 of 5 stars$3.90+0.9%$9.00+131.1%-37.4%$28.51M$7M-0.4060CVKDCadrenal Therapeutics3.2091 of 5 stars$13.54+3.8%$32.00+136.3%+71.7%$27.76MN/A-1.524TENXTenax Therapeutics1.6993 of 5 stars$5.95-1.0%$17.00+185.7%+43.1%$27.13MN/A-6.479MIRAMIRA Pharmaceuticals3.3028 of 5 stars$1.42-4.1%$17.00+1,097.2%-29.3%$27.08MN/A-2.902Gap Up Related Companies and Tools Related Companies Mural Oncology Alternatives Mana Capital Acquisition Alternatives JATT Acquisition Alternatives BioXcel Therapeutics Alternatives Synergy CHC Alternatives Dyadic International Alternatives Kezar Life Sciences Alternatives Cadrenal Therapeutics Alternatives Tenax Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access